Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS clinics say the change could rock their finances to the core, and they are pushing back hard against it.
Gilead said in an April 8 statement that “dispensing pharmacies will be reimbursed for the amount paid for each bottle plus a dispensing fee and an administrative fee.” The company said the change “will help strengthen the program model so we can help eligible people living with and at risk for HIV access their free Gilead medication for years to come, while also continuing to drive innovation that expands options for HIV treatment and prevention.”
Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS clinics say the change could rock their finances to the core, and they are pushing back hard against it.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
